House lawmakers joined a group of senators in pressing CMS to make changes to the final Clinical Laboratory Fee Schedule rule to better reflect Congress' intent and to delay the rule's implementation deadline. “Under CMS's current proposal, a number of laboratories are prohibited from participating in the reporting process. We are deeply concerned that this prohibition will skew the market data, resulting in Medicare rates that are not reflective of true market prices. We recommend that CMS consider a more...